CA19-9 及CA125评估胰腺导管腺癌的可切除性

doi:10.16139/j.1007-9610.2019.02.016

摘要/Abstract

摘要： 目的探讨血清学肿瘤指标CA19-9及CA125升高程度与胰腺导管腺癌术前可切除性评估的关系。方法回顾性分析 2009年1月至2015年12月于我院病理诊断为胰腺导管腺癌,术前影像学检查诊断肿瘤可切除病人行手术441例病人的临床资料。将病人按术中实际完成R0切除分为可切除组及不可切除组。对两组病人术前CA19-9及CA125进行比较分析。结果 CA19-9、CA125升高水平在可切除组与不可切除组之间差异有显著统计学意义（P<0.001）。将直接胆红素>34.2 μmol/L病人的CA19-9校正后,两组间CA19-9差异仍有显著统计学意义（P<0.001）。经过Logistic多因素分析筛选及受试者工作曲线后选择CA19-9（截断值=582.10 U/mL,校正后CA19-9截断值=449.70 U/mL）及CA125（截断值=41.45 U/mL）作为胰腺导管腺癌术前肿瘤可切除性的预测指标。结论胰腺导管腺癌术前血清CA19-9及CA125升高水平可作为肿瘤可切除性的辅助预测指标,高于截断值的病人可能无法施行R0切除。

关键词: 胰腺导管腺癌, CA19-9, CA125, 可切除性

Abstract: Objective To investigate the effect of increase extent of serum CA19-9 and CA125 in predicting resectability of pancreatic ductal adenocarcinoma preoperatively. Methods From January 2009 to December 2015, the clinical data of 441 patients with pancreatic ductal adenocarcinoma who were diagnosed pathologically and were evaluated to be resectable by radiology in our hospital were retrospectively analyzed. Patients were divided into resectable group and non-resectable group according to R0 resection. Preoperative serologic tumor markers including CA 19-9 and CA 125 in 2 groups were analyzed. Results There was significant statistical difference in CA19-9 and CA125 between resectable group and non-resectable group (P< 0.001). After correction of CA19-9 in the patients with direct bilirubin higher than 34.2 μmol/L, significant statistical difference in CA19-9 between two groups was still present (P< 0.001). Logistics multiple regression analysis and ROC curve showed that CA19-9 (cut-off= 582.10 U /mL, and adjusted CA19-9 cut-off= 449.70 U/mL) and CA125 (cut-off= 41.45 U/mL) were selected as predicting markers in resectability of pancreatic ductal adenocarcinoma. Conclusions Preoperative increase extent of CA19-9 and CA125 could assist to predict resectability of pancreatic ductal adenocarcinoma. The patients will have no chance of R0 resection when tumor markers increase more than cut-off value.

Key words: Pancreatic ductal adenocarcinoma, CA19-9, CA125, Resectability

中图分类号:

R735.9

李凡露, 吴志翀, 詹茜, 沈柏用. CA19-9 及CA125评估胰腺导管腺癌的可切除性[J]. 外科理论与实践, 2019, 24(02): 163-167.

LI Fanlu, WU Zhichong, ZHAN Qian, SHEN Baiyong. Validation of CA19-9, CA125in predicting respectability of pancreatic ductal adenocarcinoma[J]. Journal of Surgery Concepts & Practice, 2019, 24(02): 163-167.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[3] Dumitra S, Jamal MH, Aboukhalil J, et al.Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score[J]. HPB (Oxford),2013,15(12):1002-1009.
[4] 李宁, 沈世强, 刘建超. 血清CA19-9, CA242, CEA及CA125在胰腺癌诊断和预后中的价值[J]. 中国普外基础与临床杂志,2011,18(3):300-304.
[5] Chen T, Zhang MG, Xu HX, et al.Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma[J]. Medicine (Baltimore),2015,94(19):e751.
[6] Liu L, Xu HX, Wang WQ, et al.Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden[J]. Oncotarget,2016,7(5):5943-5956.
[7] 白燕南, 严茂林. 胰腺癌综合诊治指南(2018版)外科相关部分解读[J]. 中国普外基础与临床杂志,2018,25(6):669-672.
[8] Hirano K, Kawa S, Oguchi H, et al.Loss of lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels[J]. J Natl Cancer Inst,1987, 79(6):1261-1268.
[9] Kang CM, Kim JY, Choi GH, et al.The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer[J]. J Surg Res,2007,140(1):31-35.
[10] Humphris JL, Chang DK, Johns AL, et al.The prognostic and predictive value of serum CA19.9 in pancreatic cancer[J]. Ann Oncol,2012,23(7):1713-1722.
[11] Chan A, Prassas I, Dimitromanolakis A, et al.Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer[J]. Clin Cancer Res,2014,20(22):5787-5795.
[12] 吴文辉, 肖隆斌, 杨世斌, 等. 监测血清肿瘤标志物水平预测结肠癌根治术后复发或转移的意义[J]. 消化肿瘤杂志(电子版),2010,2(2):93-96.
[13] Yang C, Cheng H, Luo G, et al.The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system[J]. Eur J Surg Oncol,2017,43(11):2112-2118.
[14] Ni XG, Bai XF, Mao YL, et al.The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer[J]. Eur J Surg Oncol,2005, 31(2):164-169.
[15] Im HJ, Oo S, Jung W, et al.Prognostic value of metabo-lic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer[J]. Medicine (Baltimore),2016,95(19):e3686.